Abraxane (Paclitaxel Protein-Bound) Patent Expiration, LOE Window & CMS Spending

Abraxane (Paclitaxel Protein-Bound) by Bristol Myers Squibb: FDA Orange Book LOE 2034-07-12, 4 AB generics, $39.6M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBristol Myers Squibb
FDA Application & PathwayN021660 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2034-07-12
Orange Book Patents (*PED Extensions)14 patents (7 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$39.6M
2024 Medicare Part D Spend$7.2M
2024 Medicaid Spend$32.4M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.